Page 143 Cite

Suggested Citation:"Appendix B: Committee Meeting 2 Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.

×

B

Committee Meeting 2 Agenda

COMMITTEE ON A NATIONAL STRATEGY FOR THE ELIMINATION OF HEPATITIS B AND C

The Keck Center, 500 Fifth Street NW
Washington, DC 20001

December 16, 2015
Room 105

THE SCIENTIFIC AND CLINICAL FEASIBILITY OF ELIMINATING HCV

8:45-9:00	Welcome and Introductions Brian Strom,Committee Chair
9:00-9:30	The Epidemiology and Natural History of Hepatitis C Virus David Thomas,Professor of Medicine and Director of Infectious Diseases, Johns Hopkins University School of Medicine
9:30-10:00	Screening and Clinical Management of Hepatitis C Marc Ghany,Staff Clinician, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health

Page 144 Cite

Suggested Citation:"Appendix B: Committee Meeting 2 Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.

×

10:00-10:30	Treatment of Hepatitis C Jay Hoofnagle,Director, Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
10:30-10:45	Break
10:45-11:15	Prevalence of HCV and a Framework for Understanding Cost-Effectiveness Arthur Kim,Director Viral Hepatitis Clinic, Massachusetts General Hospital
11:15-12:30	Panel Discussion on the Scientific and Clinical Feasibility of Eliminating HCV Stuart Ray,Moderator David Thomas,Professor of Medicine and Director of Infectious Diseases, Johns Hopkins University School of Medicine Marc Ghany,Staff Clinician, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Jay Hoofnagle,Deputy Director, Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Arthur Kim,Director Viral Hepatitis Clinic, Massachusetts General Hospital

THE LOGISTICAL AND SOCIAL FEASIBILITY OF ELIMINATING HCV

1:30-2:00	Price and Access to Hepatitis C Drugs Camilla Graham,Assistant Professor of Medicine, Beth Israel Deaconess Medical Center
2:00-2:30	The National Infrastructure for Hepatitis C: Is There Anyone Home? Daniel O’Connell,Director, New York State Department of Health AIDS Institute
2:30-2:45	Break

Page 145 Cite

Suggested Citation:"Appendix B: Committee Meeting 2 Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.

×

2:45-3:15	The Feasibility of Eliminating Hepatitis C Among Injection Drug Users Brian Edlin,Senior Principal Investigator, Institute for Infectious Disease Research National Development and Research Institutes
3:15-3:45	The Logistics of Reaching the Hepatitis C Patient in Corrections Lara Strick,Infectious Disease Specialist, Washington State Department of Corrections (by video)
3:45-5:00	Panel Discussion on the Logistical and Social Feasibility of Eliminating HCV Paul Kuehnert, Moderator Camilla Graham,Assistant Professor of Medicine, Beth Israel Deaconess Medical Center Brian Edlin,Senior Principal Investigator, Institute for Infectious Disease Research National Development and Research Institutes Daniel O’Connell,Director, New York State Department of Health AIDS Institute

Page 146 Cite

Suggested Citation:"Appendix B: Committee Meeting 2 Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.

×